Taking the Long View in Improving Adherence to Immunosuppressant Therapy in Transplant Recipients

CMEO Medical Meeting

Symposium Date: Wednesday, July 30, 2014
World Transplant Congress July 30, 2014
San Francisco Marriott Marquis
Golden Gate A/B
San Francisco, CA

This activity offers CE credit for:

  1. Physicians (CME)
  2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, July 30, 2015


Flavio Vincenti, MD Flavio Vincenti, MD 
Professor of Clinical Medicine and Surgery
Departments of Medicine and Surgery

University of California, San Francisco
San Francisco, CA

Gabriel M. Danovitch, MD Gabriel M. Danovitch, MD 
Professor of Medicine
University of California Los Angeles
Medical Director, Kidney and Pancreas Transplantation
Ronald Reagan Medical Center at UCLA
Los Angeles, CA

Simin Goral, MD Simin Goral, MD 
Professor of Medicine
Renal Electrolyte and Hypertension Division
University of Pennsylvania School of Medicine
Philadelphia, PA

Donald E. Hricik, MD Donald E. Hricik, MD 
Chief, Division of Nephrology and Hypertension
Interim Director, Transplant Institute
Medical Director, Kidney and Pancreas Transplantation
University Hospitals Case Medical Center
Cleveland, OH

Statement of Need

Kidney transplant recipients live an average of 10 to 15 years longer than patients on dialysis.1 Short-term survival rates of transplanted kidneys are quite good, and approximately 95% are functioning well one year after surgery.(1) Although short-term prognoses have improved considerably in recent years, the magnitude of improvement in long-term, patient outcomes has been less significant. Although adherence to immunosuppressant regimen is critical, a meta-analysis by Dew and colleagues reported a mean immunosuppressant non-adherence prevalence of approximately 36% among renal transplant recipients.(2) Lack of adherence to prescribed immunosuppressant medication increases transplant recipients’ likelihood of graft rejection or failure, and can result in increased health complications, health care costs, and death. Immunosuppressant non-adherence manifests in several forms—from taking a medication at the wrong time to not taking it at all and can be driven by medical and social issues.

This unique and highly interactive case-based symposium will put the participants at the center of the discussion and development of a treatment plan for the onsite patient. The expert-learner collaboration will focus on increasing clinician awareness of the core issues related to prolonging the life of an allograft over time, including the delicate balance of the immunosuppressants, managing side effects of the medication, and identifying medical and social barriers to patient adherence to prescribed treatments resulting in improved quality of life and long-term patient outcomes.

  1. Dion-Labrie M, Fortin MC, Hébert MJ, Doucet H. The use of personalized medicine for patient selection for renal transplantation: physicians' views on the clinical and ethical implications. BMC Med Ethics. 2010;11:15. PMID: 20380726
  2. Macready N. Adherence efforts go high-tech. Am J Transplant. 2012;12(9):2263-2264. PMID: 22925180.

Activity Goal

This educational activity centers on the CMEO Make-One-Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make-One-Change Statement for this activity is:

Discuss adherence to immunosuppressant medications with all transplant patients at every visit and empower them with resources that they can integrate into daily activities.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Adopt a patient-centered approach to the management of kidney transplant recipients by regularly assessing and discussing adherence to long-term immunosuppression and the impact of adherence on long-term patient outcomes.
  • Devise and implement a personalized treatment plan with each patient that uses the immunosuppressive strategies to minimize long-term allograft rejection in patients receiving kidney transplants.

Financial Support

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Target Audience

Physicians and other health care professionals who are interested in the management of kidney transplant recipients.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST895 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure of Relevant Financial Relationships with Commercial Interests

CME Outfitters, LLC adheres to the ACCME Standards, as well as those of the ACPE, and CBRN, regarding commercial support of continuing medical education. It is the policy of CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Relevant financial relationships exist between the following individuals and commercial interests:

Dr. Vincenti has disclosed that he has received research support from Alexion; Astellas Scientific and Medical Affairs, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; and Pfizer Inc.

Dr. Danovitch has nothing to disclose.

Dr. Goral has disclosed that she has received research support from Bristol-Myers Squibb Company; Otsuka America Pharmaceuticals, Inc.; and Keryx Biopharmaceuticals, Inc. She serves on the speakers bureau of Sanofi-aventis.

Dr. Hricik has disclosed that he serves on the speakers bureau for Genentech, Inc. and is a consultant for Oxford Immunotec, Inc.

Ahmad Safra, MD (peer reviewer) has nothing to disclose.

Robert Kennedy, MA (planning committee) has nothing to disclose.

Sharon Tordoff, CCMEP (planning committee) has nothing to disclose

Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.

Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and Novartis Corporation, Inc., do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Equal Opportunity Statement: Events, activities, and programs are available to all without regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabled veteran status as provided by law and in accordance with the university's respect for personal dignity.

CME Outfitters reserves the right to cancel this program due to unforeseen circumstances. In the unlikely event of such cancellation, CME Outfitters will not be responsible for travel expenses incurred by the participant.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

This document was last modified on: